RecruitingNot Applicable

A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA

United States900 participantsStarted 2023-03-20

Plain-language summary

The goal of this study is to genrate evidence on long-term effectiveness and safety of SKYTROFA (lonapegsomatropin) in patients with growth hormone deficiency under routine clinical care

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients who are on treatment with SKYTROFA (lonapegsomatropin) * Patients being clinically managed in USA * Patients with an appropriate written informed consent/assent as applicable for the age of the patient Exclusion Criteria: * Patients participating in any interventional clinical study

What they're measuring

Assess the safety of patients treated with SKYTROFA (Lonapegsomatropin)

Timeframe: 5 years

Assess the effectiveness of patients treated with SKYTROFA (Lonapegsomatropin)

Timeframe: 5 years

Trial details

NCT IDNCT05820672

SponsorAscendis Pharma Endocrinology Division A/S

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2033-03

Contact for this trial

Deborah Bowlby

+1 844-442-7236 Skybright_contact@ascendispharma.com

View on ClinicalTrials.gov More Growth Hormone Deficiency trials